Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare GW766944 (an Oral CCR3 Receptor Antagonist) Versus Placebo in Patients With Asthma and Sputum Eosinophilia.

NCT01160224 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01160224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01160224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare GW766944 (an Oral CCR3 Receptor Antagonist) Versus Placebo in Patients With Asthma and Sputum Eosinophilia.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
September 8, 2010
Completion date
August 29, 2011
Enrollment
60 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

asthma